Benchmark Downgrades Humacyte to Speculative Buy, Lowers Price Target to $1

Benchmark analyst Bruce D. Jackson has downgraded Humacyte (NASDAQ: HUMA) from a 'Buy' rating to 'Speculative Buy' and reduced the price target from $10 to $1.